IL201217A - A method for determining and identifying a marker for breast cancer susceptibility - Google Patents
A method for determining and identifying a marker for breast cancer susceptibilityInfo
- Publication number
- IL201217A IL201217A IL201217A IL20121709A IL201217A IL 201217 A IL201217 A IL 201217A IL 201217 A IL201217 A IL 201217A IL 20121709 A IL20121709 A IL 20121709A IL 201217 A IL201217 A IL 201217A
- Authority
- IL
- Israel
- Prior art keywords
- allele
- breast cancer
- markers
- marker
- risk
- Prior art date
Links
- 206010006187 Breast cancer Diseases 0.000 title claims description 492
- 208000026310 Breast neoplasm Diseases 0.000 title claims description 485
- 239000003550 marker Substances 0.000 title claims description 294
- 238000000034 method Methods 0.000 title claims description 215
- 108700028369 Alleles Proteins 0.000 claims description 864
- 102000054766 genetic haplotypes Human genes 0.000 claims description 306
- 239000000523 sample Substances 0.000 claims description 220
- 150000007523 nucleic acids Chemical class 0.000 claims description 173
- 102000039446 nucleic acids Human genes 0.000 claims description 159
- 108020004707 nucleic acids Proteins 0.000 claims description 159
- 206010028980 Neoplasm Diseases 0.000 claims description 109
- 239000002773 nucleotide Substances 0.000 claims description 105
- 125000003729 nucleotide group Chemical group 0.000 claims description 105
- 230000002068 genetic effect Effects 0.000 claims description 102
- 102210006767 rs3803662 Human genes 0.000 claims description 99
- 230000001965 increasing effect Effects 0.000 claims description 86
- 201000010099 disease Diseases 0.000 claims description 81
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 81
- 238000011282 treatment Methods 0.000 claims description 73
- 238000004458 analytical method Methods 0.000 claims description 72
- 108020004414 DNA Proteins 0.000 claims description 64
- 238000001514 detection method Methods 0.000 claims description 59
- 101150008921 Brca2 gene Proteins 0.000 claims description 58
- 108700020462 BRCA2 Proteins 0.000 claims description 56
- 102000052609 BRCA2 Human genes 0.000 claims description 56
- 238000003745 diagnosis Methods 0.000 claims description 45
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims description 44
- 239000002751 oligonucleotide probe Substances 0.000 claims description 44
- 108091034117 Oligonucleotide Proteins 0.000 claims description 43
- 238000009396 hybridization Methods 0.000 claims description 41
- 238000003556 assay Methods 0.000 claims description 37
- 239000003814 drug Substances 0.000 claims description 37
- 230000003247 decreasing effect Effects 0.000 claims description 32
- 230000000295 complement effect Effects 0.000 claims description 31
- 239000003623 enhancer Substances 0.000 claims description 30
- 239000003153 chemical reaction reagent Substances 0.000 claims description 27
- 102000015694 estrogen receptors Human genes 0.000 claims description 25
- 108010038795 estrogen receptors Proteins 0.000 claims description 25
- 239000012634 fragment Substances 0.000 claims description 24
- 230000004044 response Effects 0.000 claims description 22
- 102000003998 progesterone receptors Human genes 0.000 claims description 20
- 108090000468 progesterone receptors Proteins 0.000 claims description 20
- 238000012502 risk assessment Methods 0.000 claims description 19
- 229940124597 therapeutic agent Drugs 0.000 claims description 19
- 239000013068 control sample Substances 0.000 claims description 17
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 16
- 238000003205 genotyping method Methods 0.000 claims description 16
- 238000003752 polymerase chain reaction Methods 0.000 claims description 12
- 238000004393 prognosis Methods 0.000 claims description 12
- 230000007423 decrease Effects 0.000 claims description 8
- 238000012544 monitoring process Methods 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 238000012163 sequencing technique Methods 0.000 claims description 8
- 108010042407 Endonucleases Proteins 0.000 claims description 7
- 230000003321 amplification Effects 0.000 claims description 7
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 7
- 230000029087 digestion Effects 0.000 claims description 6
- 238000005259 measurement Methods 0.000 claims description 5
- 230000004224 protection Effects 0.000 claims description 5
- 238000011325 biochemical measurement Methods 0.000 claims description 4
- 239000012830 cancer therapeutic Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000010791 quenching Methods 0.000 claims description 4
- 230000000171 quenching effect Effects 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- 108010010677 Phosphodiesterase I Proteins 0.000 claims description 2
- 102000004533 Endonucleases Human genes 0.000 claims 3
- 238000001712 DNA sequencing Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 177
- 239000003795 chemical substances by application Substances 0.000 description 119
- 229920001184 polypeptide Polymers 0.000 description 71
- 102000004196 processed proteins & peptides Human genes 0.000 description 71
- 108090000765 processed proteins & peptides Proteins 0.000 description 71
- 230000014509 gene expression Effects 0.000 description 69
- 102000004169 proteins and genes Human genes 0.000 description 65
- 239000000969 carrier Substances 0.000 description 59
- 101710147238 Metalloreductase STEAP3 Proteins 0.000 description 58
- 102100037653 Metalloreductase STEAP3 Human genes 0.000 description 56
- 238000012360 testing method Methods 0.000 description 56
- 230000035772 mutation Effects 0.000 description 53
- 201000011510 cancer Diseases 0.000 description 47
- 239000013615 primer Substances 0.000 description 41
- 210000000349 chromosome Anatomy 0.000 description 37
- 210000004027 cell Anatomy 0.000 description 34
- 102000054765 polymorphisms of proteins Human genes 0.000 description 31
- 230000006798 recombination Effects 0.000 description 30
- 238000005215 recombination Methods 0.000 description 30
- 108020004999 messenger RNA Proteins 0.000 description 29
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 26
- 230000000694 effects Effects 0.000 description 26
- 238000012216 screening Methods 0.000 description 25
- 230000037361 pathway Effects 0.000 description 24
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 22
- 230000002596 correlated effect Effects 0.000 description 21
- 239000000203 mixture Substances 0.000 description 21
- 210000001519 tissue Anatomy 0.000 description 21
- 238000002560 therapeutic procedure Methods 0.000 description 20
- 238000001959 radiotherapy Methods 0.000 description 19
- 230000010076 replication Effects 0.000 description 19
- 229940079593 drug Drugs 0.000 description 18
- 108091092878 Microsatellite Proteins 0.000 description 15
- 108091028043 Nucleic acid sequence Proteins 0.000 description 15
- 210000000481 breast Anatomy 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- WGZDBVOTUVNQFP-UHFFFAOYSA-N N-(1-phthalazinylamino)carbamic acid ethyl ester Chemical compound C1=CC=C2C(NNC(=O)OCC)=NN=CC2=C1 WGZDBVOTUVNQFP-UHFFFAOYSA-N 0.000 description 14
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 14
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 14
- 150000001413 amino acids Chemical group 0.000 description 14
- 230000000875 corresponding effect Effects 0.000 description 14
- 230000009368 gene silencing by RNA Effects 0.000 description 14
- 239000002853 nucleic acid probe Substances 0.000 description 14
- 230000004075 alteration Effects 0.000 description 13
- 108700020463 BRCA1 Proteins 0.000 description 12
- 102000036365 BRCA1 Human genes 0.000 description 12
- 101150072950 BRCA1 gene Proteins 0.000 description 12
- 101000679548 Homo sapiens TOX high mobility group box family member 3 Proteins 0.000 description 12
- 108020004459 Small interfering RNA Proteins 0.000 description 12
- 239000004055 small Interfering RNA Substances 0.000 description 12
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 11
- 230000000692 anti-sense effect Effects 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 238000002512 chemotherapy Methods 0.000 description 11
- 239000002299 complementary DNA Substances 0.000 description 11
- 238000005516 engineering process Methods 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 230000001681 protective effect Effects 0.000 description 11
- 229960001603 tamoxifen Drugs 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 10
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 10
- 230000008859 change Effects 0.000 description 10
- 238000012217 deletion Methods 0.000 description 10
- 230000037430 deletion Effects 0.000 description 10
- 238000011161 development Methods 0.000 description 10
- 229940088598 enzyme Drugs 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 230000007774 longterm Effects 0.000 description 10
- 239000002987 primer (paints) Substances 0.000 description 10
- 230000002441 reversible effect Effects 0.000 description 10
- 238000001356 surgical procedure Methods 0.000 description 10
- 101001128634 Homo sapiens NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 2, mitochondrial Proteins 0.000 description 9
- 102100032194 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 2, mitochondrial Human genes 0.000 description 9
- 238000004422 calculation algorithm Methods 0.000 description 9
- 230000002113 chemopreventative effect Effects 0.000 description 9
- 238000013461 design Methods 0.000 description 9
- 238000003657 Likelihood-ratio test Methods 0.000 description 8
- 108091093037 Peptide nucleic acid Proteins 0.000 description 8
- 230000007613 environmental effect Effects 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 102210003522 rs4784227 Human genes 0.000 description 8
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 8
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 8
- 238000010561 standard procedure Methods 0.000 description 8
- 206010060862 Prostate cancer Diseases 0.000 description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 238000012098 association analyses Methods 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- 210000004408 hybridoma Anatomy 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 238000007726 management method Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 238000011277 treatment modality Methods 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 102100037140 BCL2/adenovirus E1B 19 kDa protein-interacting protein 3-like Human genes 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 6
- 101000740545 Homo sapiens BCL2/adenovirus E1B 19 kDa protein-interacting protein 3-like Proteins 0.000 description 6
- 206010027476 Metastases Diseases 0.000 description 6
- 108091027967 Small hairpin RNA Proteins 0.000 description 6
- 238000003491 array Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000012937 correction Methods 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 230000009401 metastasis Effects 0.000 description 6
- CJWXCNXHAIFFMH-AVZHFPDBSA-N n-[(2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5r)-2-acetamido-4,5,6-trihydroxy-1-oxohexan-3-yl]oxy-3,5-dihydroxy-6-methyloxan-4-yl]acetamide Chemical compound C[C@H]1O[C@@H](O[C@@H]([C@@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O)[C@H](O)[C@@H](NC(C)=O)[C@@H]1O CJWXCNXHAIFFMH-AVZHFPDBSA-N 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- 206010067484 Adverse reaction Diseases 0.000 description 5
- 108700010154 BRCA2 Genes Proteins 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 102100036049 T-complex protein 1 subunit gamma Human genes 0.000 description 5
- 230000006838 adverse reaction Effects 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 239000003886 aromatase inhibitor Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 101150062912 cct3 gene Proteins 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 210000001808 exosome Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000001794 hormone therapy Methods 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 229910052742 iron Inorganic materials 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 238000002966 oligonucleotide array Methods 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 230000000069 prophylactic effect Effects 0.000 description 5
- 229960004622 raloxifene Drugs 0.000 description 5
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 5
- 230000007115 recruitment Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000008439 repair process Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 229940122815 Aromatase inhibitor Drugs 0.000 description 4
- 108010004586 Ataxia Telangiectasia Mutated Proteins Proteins 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 102100031780 Endonuclease Human genes 0.000 description 4
- 108010076070 HSCH2CH(CH2CH(CH3)2)CO-Phe-Ala-NH2 Proteins 0.000 description 4
- 238000007476 Maximum Likelihood Methods 0.000 description 4
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 238000012300 Sequence Analysis Methods 0.000 description 4
- 238000011226 adjuvant chemotherapy Methods 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000003197 gene knockdown Methods 0.000 description 4
- 230000030279 gene silencing Effects 0.000 description 4
- 238000012252 genetic analysis Methods 0.000 description 4
- 230000009395 genetic defect Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 238000002595 magnetic resonance imaging Methods 0.000 description 4
- 238000009607 mammography Methods 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 210000004940 nucleus Anatomy 0.000 description 4
- 238000013439 planning Methods 0.000 description 4
- 230000009862 primary prevention Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 3
- 238000000729 Fisher's exact test Methods 0.000 description 3
- 102100040004 Gamma-glutamylcyclotransferase Human genes 0.000 description 3
- 206010071602 Genetic polymorphism Diseases 0.000 description 3
- 208000033640 Hereditary breast cancer Diseases 0.000 description 3
- 101000886680 Homo sapiens Gamma-glutamylcyclotransferase Proteins 0.000 description 3
- 101000880402 Homo sapiens Metalloreductase STEAP4 Proteins 0.000 description 3
- 101000777277 Homo sapiens Serine/threonine-protein kinase Chk2 Proteins 0.000 description 3
- 102100037654 Metalloreductase STEAP4 Human genes 0.000 description 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 3
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 3
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 3
- 102100022608 TOX high mobility group box family member 3 Human genes 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 239000000074 antisense oligonucleotide Substances 0.000 description 3
- 238000012230 antisense oligonucleotides Methods 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000002759 chromosomal effect Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 210000001163 endosome Anatomy 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000037433 frameshift Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 238000012226 gene silencing method Methods 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 230000007614 genetic variation Effects 0.000 description 3
- 208000025581 hereditary breast carcinoma Diseases 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 238000007901 in situ hybridization Methods 0.000 description 3
- 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 239000002679 microRNA Substances 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000002823 phage display Methods 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 230000009863 secondary prevention Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000004088 simulation Methods 0.000 description 3
- 238000013517 stratification Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 2
- 241000722946 Acanthocybium solandri Species 0.000 description 2
- 102100039164 Acetyl-CoA carboxylase 1 Human genes 0.000 description 2
- 102100039819 Actin, alpha cardiac muscle 1 Human genes 0.000 description 2
- VWEWCZSUWOEEFM-WDSKDSINSA-N Ala-Gly-Ala-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(O)=O VWEWCZSUWOEEFM-WDSKDSINSA-N 0.000 description 2
- 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
- 101150064168 CHEK2 gene Proteins 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108020003215 DNA Probes Proteins 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 241001397104 Dima Species 0.000 description 2
- 101150029707 ERBB2 gene Proteins 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000963424 Homo sapiens Acetyl-CoA carboxylase 1 Proteins 0.000 description 2
- 101000959247 Homo sapiens Actin, alpha cardiac muscle 1 Proteins 0.000 description 2
- 101000678026 Homo sapiens Alpha-1-antichymotrypsin Proteins 0.000 description 2
- 101100220617 Homo sapiens CHEK2 gene Proteins 0.000 description 2
- 101000628547 Homo sapiens Metalloreductase STEAP1 Proteins 0.000 description 2
- 101000628535 Homo sapiens Metalloreductase STEAP2 Proteins 0.000 description 2
- 241001425930 Latina Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102100026712 Metalloreductase STEAP1 Human genes 0.000 description 2
- 102100026711 Metalloreductase STEAP2 Human genes 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 108020004485 Nonsense Codon Proteins 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000035327 Oestrogen receptor positive breast cancer Diseases 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 102100029812 Protein S100-A12 Human genes 0.000 description 2
- 101710110949 Protein S100-A12 Proteins 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 108010005173 SERPIN-B5 Proteins 0.000 description 2
- 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 description 2
- 102100030333 Serpin B5 Human genes 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 102100029887 Translationally-controlled tumor protein Human genes 0.000 description 2
- 101710175870 Translationally-controlled tumor protein homolog Proteins 0.000 description 2
- 206010047249 Venous thrombosis Diseases 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 210000004381 amniotic fluid Anatomy 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 238000012093 association test Methods 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000000981 bystander Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 description 2
- 210000001723 extracellular space Anatomy 0.000 description 2
- 201000007741 female breast cancer Diseases 0.000 description 2
- 201000002276 female breast carcinoma Diseases 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000003209 gene knockout Methods 0.000 description 2
- 102000054767 gene variant Human genes 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000003447 ipsilateral effect Effects 0.000 description 2
- 238000007477 logistic regression Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000000869 mutational effect Effects 0.000 description 2
- 238000009806 oophorectomy Methods 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 230000002974 pharmacogenomic effect Effects 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 230000003234 polygenic effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000861 pro-apoptotic effect Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 230000004853 protein function Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000012857 radioactive material Substances 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 102210010853 rs2193094 Human genes 0.000 description 2
- 208000011581 secondary neoplasm Diseases 0.000 description 2
- 210000004739 secretory vesicle Anatomy 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 229940126586 small molecule drug Drugs 0.000 description 2
- 238000011895 specific detection Methods 0.000 description 2
- 230000004960 subcellular localization Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 238000012384 transportation and delivery Methods 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 101150028074 2 gene Proteins 0.000 description 1
- PIINGYXNCHTJTF-UHFFFAOYSA-N 2-(2-azaniumylethylamino)acetate Chemical group NCCNCC(O)=O PIINGYXNCHTJTF-UHFFFAOYSA-N 0.000 description 1
- 102100039217 3-ketoacyl-CoA thiolase, peroxisomal Human genes 0.000 description 1
- 102100033400 4F2 cell-surface antigen heavy chain Human genes 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- 102000000872 ATM Human genes 0.000 description 1
- 208000035657 Abasia Diseases 0.000 description 1
- 241000023308 Acca Species 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- 108010000239 Aequorin Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 1
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 102100029361 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 101700002522 BARD1 Proteins 0.000 description 1
- 108700040618 BRCA1 Genes Proteins 0.000 description 1
- 102100028048 BRCA1-associated RING domain protein 1 Human genes 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 101150017888 Bcl2 gene Proteins 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 206010006253 Breast fibrosis Diseases 0.000 description 1
- 101100311222 Caenorhabditis elegans stam-1 gene Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 208000016216 Choristoma Diseases 0.000 description 1
- 244000175448 Citrus madurensis Species 0.000 description 1
- 235000004332 Citrus madurensis Nutrition 0.000 description 1
- 235000007438 Citrus mitis Nutrition 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000036493 Contralateral breast cancer Diseases 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 108010036364 Deoxyribonuclease IV (Phage T4-Induced) Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101000995602 Escherichia coli (strain K12) Type II NADH:quinone oxidoreductase Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 230000020172 G2/M transition checkpoint Effects 0.000 description 1
- 240000005702 Galium aparine Species 0.000 description 1
- 235000014820 Galium aparine Nutrition 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 208000034951 Genetic Translocation Diseases 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- 101000800023 Homo sapiens 4F2 cell-surface antigen heavy chain Proteins 0.000 description 1
- 101100153048 Homo sapiens ACAA1 gene Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 1
- 206010073094 Intraductal proliferative breast lesion Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 206010073099 Lobular breast carcinoma in situ Diseases 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 208000004059 Male Breast Neoplasms Diseases 0.000 description 1
- 241000997826 Melanocetus johnsonii Species 0.000 description 1
- 206010027540 Microcytosis Diseases 0.000 description 1
- 108700011325 Modifier Genes Proteins 0.000 description 1
- 208000008770 Multiple Hamartoma Syndrome Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000010645 MutS Proteins Human genes 0.000 description 1
- 108010038272 MutS Proteins Proteins 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 102400000058 Neuregulin-1 Human genes 0.000 description 1
- 108090000556 Neuregulin-1 Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 241000287107 Passer Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 241000364051 Pima Species 0.000 description 1
- 231100000742 Plant toxin Toxicity 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 208000030555 Pygmy Diseases 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 208000033722 Rare malignant breast tumor Diseases 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 102100029831 Reticulon-4 Human genes 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 229940122055 Serine protease inhibitor Drugs 0.000 description 1
- 101710102218 Serine protease inhibitor Proteins 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 108010033576 Transferrin Receptors Proteins 0.000 description 1
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 208000022440 X-linked sideroblastic anemia 1 Diseases 0.000 description 1
- WCDYMMVGBZNUGB-ORPFKJIMSA-N [(2r,3r,4s,5r,6r)-6-[[(1r,3r,4r,5r,6r)-4,5-dihydroxy-2,7-dioxabicyclo[4.2.0]octan-3-yl]oxy]-3,4,5-trihydroxyoxan-2-yl]methyl 3-hydroxy-2-tetradecyloctadecanoate Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](COC(=O)C(CCCCCCCCCCCCCC)C(O)CCCCCCCCCCCCCCC)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H]2OC[C@H]2O1 WCDYMMVGBZNUGB-ORPFKJIMSA-N 0.000 description 1
- DUDJTRNGXIUJEB-UHFFFAOYSA-N [N].NCC(O)=O Chemical group [N].NCC(O)=O DUDJTRNGXIUJEB-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000007844 allele-specific PCR Methods 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 125000006295 amino methylene group Chemical group [H]N(*)C([H])([H])* 0.000 description 1
- 108010025592 aminoadipoyl-cysteinyl-allylglycine Proteins 0.000 description 1
- 238000002669 amniocentesis Methods 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000003172 anti-dna Effects 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000003443 anti-oncogenic effect Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 238000007846 asymmetric PCR Methods 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 201000005389 breast carcinoma in situ Diseases 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 230000017075 cellular response to radiation Effects 0.000 description 1
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N chembl421 Chemical compound C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000012707 chemical precursor Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000004252 chorionic villi Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000003936 denaturing gel electrophoresis Methods 0.000 description 1
- 238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 230000005782 double-strand break Effects 0.000 description 1
- 230000012361 double-strand break repair Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 1
- 201000007273 ductal carcinoma in situ Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000001819 effect on gene Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 108010091897 factor V Leiden Proteins 0.000 description 1
- 108010035554 ferric citrate iron reductase Proteins 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 150000002243 furanoses Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 229940080856 gleevec Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 208000006278 hypochromic anemia Diseases 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 208000030776 invasive breast carcinoma Diseases 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 201000011059 lobular neoplasia Diseases 0.000 description 1
- 238000011454 long-term hormonal therapy Methods 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 201000003175 male breast cancer Diseases 0.000 description 1
- 208000010907 male breast carcinoma Diseases 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 208000016044 mixed lobular and ductal breast carcinoma Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 230000003990 molecular pathway Effects 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical class O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 238000007826 nucleic acid assay Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 230000000177 oncogenetic effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 108700025694 p53 Genes Proteins 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 102000045222 parkin Human genes 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 238000001558 permutation test Methods 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 210000004214 philadelphia chromosome Anatomy 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 239000003123 plant toxin Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 230000024715 positive regulation of secretion Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 201000007283 progesterone-receptor positive breast cancer Diseases 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 210000005267 prostate cell Anatomy 0.000 description 1
- 238000000734 protein sequencing Methods 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000003439 radiotherapeutic effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000012107 replication analysis Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 238000013058 risk prediction model Methods 0.000 description 1
- 102200081254 rs28997576 Human genes 0.000 description 1
- 102210007166 rs3112612 Human genes 0.000 description 1
- 102210018275 rs4784223 Human genes 0.000 description 1
- 102200093939 rs75466054 Human genes 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 108010066082 tartrate-sensitive acid phosphatase Proteins 0.000 description 1
- 101150075675 tatC gene Proteins 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000009752 translational inhibition Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IS8625 | 2007-03-26 | ||
| IS8648 | 2007-05-25 | ||
| PCT/IS2008/000009 WO2008117314A2 (en) | 2007-03-26 | 2008-03-26 | Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL201217A0 IL201217A0 (en) | 2010-05-31 |
| IL201217A true IL201217A (en) | 2014-03-31 |
Family
ID=39563444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL201217A IL201217A (en) | 2007-03-26 | 2009-09-29 | A method for determining and identifying a marker for breast cancer susceptibility |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20110117545A1 (enExample) |
| EP (3) | EP2137324A2 (enExample) |
| JP (1) | JP5676245B2 (enExample) |
| KR (1) | KR20090127939A (enExample) |
| CN (1) | CN101874120B (enExample) |
| AU (1) | AU2008231425B2 (enExample) |
| CA (1) | CA2681928A1 (enExample) |
| EA (1) | EA019953B1 (enExample) |
| IL (1) | IL201217A (enExample) |
| MX (1) | MX2009010439A (enExample) |
| NZ (1) | NZ580490A (enExample) |
| WO (1) | WO2008117314A2 (enExample) |
| ZA (1) | ZA200907471B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9827314B2 (en) | 2003-12-08 | 2017-11-28 | Mars, Incorporated | Edible compositions which are adapted for use by a companion animal |
| CN103710430B (zh) | 2005-11-29 | 2016-03-30 | 剑桥企业有限公司 | 乳腺癌标志物 |
| AU2009269542A1 (en) | 2008-07-07 | 2010-01-14 | Decode Genetics Ehf | Genetic variants for breast cancer risk assessment |
| CN102232116A (zh) * | 2008-10-03 | 2011-11-02 | 玛尔斯有限公司 | 用于狗肝铜积累的遗传检测和低铜宠物喂食 |
| MX2011012913A (es) * | 2009-06-01 | 2012-02-21 | Genetic Technologies Ltd | Métodos para evaluar el riesgo de cáncer de mama. |
| US8356023B2 (en) * | 2009-07-28 | 2013-01-15 | Ancestry.Com Operations Inc. | Collaborative systems and methods for constructing representations of data |
| EP2721180A4 (en) * | 2011-06-16 | 2015-09-02 | Decode Genetics Ehf | GENETIC VARIANTS FOR PREDICTING THE RISK OF BREAST CANCER |
| GB201120989D0 (en) | 2011-12-06 | 2012-01-18 | Mars Inc | Genetic test |
| KR101390590B1 (ko) * | 2012-06-28 | 2014-04-30 | 서울대학교산학협력단 | 췌장암 재발 예후 예측용 마커 및 이의 용도 |
| US10188617B2 (en) | 2013-03-12 | 2019-01-29 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of cellular DNA repair activity to intercept malignancy |
| IL251376B (en) | 2014-09-30 | 2022-09-01 | Genetic Tech Limited | Methods for assessing risk of developing breast cancer |
| KR20180132727A (ko) * | 2016-03-29 | 2018-12-12 | 리제너론 파마슈티칼스 인코포레이티드 | 유전자 변이체 표현형 분석 시스템 및 사용 방법 |
| CN108588263B (zh) * | 2018-06-07 | 2022-02-01 | 中国农业科学院烟草研究所 | 一种用于定位和克隆植物中控制同一性状的双隐性基因的方法 |
| CN108676890B (zh) * | 2018-07-12 | 2022-01-28 | 吉林大学 | 一种女性乳腺恶性肿瘤易感性预测试剂盒及系统 |
| US10395772B1 (en) * | 2018-10-17 | 2019-08-27 | Tempus Labs | Mobile supplementation, extraction, and analysis of health records |
| CA3122070A1 (en) | 2018-12-03 | 2020-06-11 | Tempus Labs, Inc. | Clinical concept identification, extraction, and prediction system and related methods |
| KR102091790B1 (ko) * | 2019-09-02 | 2020-03-20 | 주식회사 클리노믹스 | 피검사자와 생물체 간의 유전자 정보를 이용한 유전적 띠 제공 시스템 및 그 방법 |
| EP4029020A4 (en) | 2019-09-13 | 2023-09-20 | 23Andme, Inc. | Methods and systems for determining and displaying pedigrees |
| KR20240063050A (ko) * | 2022-11-02 | 2024-05-09 | 주식회사 디시젠 | 암 발생 위험도 예측 방법 |
| CN116287258B (zh) * | 2023-02-23 | 2025-08-26 | 清华大学深圳国际研究生院 | 一种新型分子标志物在乳腺癌诊断或预后评估中的应用 |
| CN119381001A (zh) * | 2025-01-02 | 2025-01-28 | 四川大学华西医院 | 一种乳腺癌复发风险的预测方法、装置、设备及存储介质 |
| CN120805003B (zh) * | 2025-09-04 | 2025-12-02 | 四川大学华西医院 | 一种基于多阶段动态优化的时序数据突变检测方法、系统和存储介质 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) * | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5143854A (en) * | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5424186A (en) * | 1989-06-07 | 1995-06-13 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis |
| US5288644A (en) * | 1990-04-04 | 1994-02-22 | The Rockefeller University | Instrument and method for the sequencing of genome |
| US5858659A (en) * | 1995-11-29 | 1999-01-12 | Affymetrix, Inc. | Polymorphism detection |
| US5837832A (en) * | 1993-06-25 | 1998-11-17 | Affymetrix, Inc. | Arrays of nucleic acid probes on biological chips |
| AU785425B2 (en) * | 2001-03-30 | 2007-05-17 | Genetic Technologies Limited | Methods of genomic analysis |
| CA2460215A1 (en) * | 2001-08-04 | 2003-02-20 | Whitehead Institute For Biomedical Research | Haplotype map of the human genome and uses therefor |
| US20040023237A1 (en) * | 2001-11-26 | 2004-02-05 | Perelegen Sciences Inc. | Methods for genomic analysis |
| US20040146870A1 (en) * | 2003-01-27 | 2004-07-29 | Guochun Liao | Systems and methods for predicting specific genetic loci that affect phenotypic traits |
| PL214402B1 (pl) * | 2003-08-11 | 2013-07-31 | Tomasz Byrski | Zastosowanie selenu albo jego zwiazku do otrzymywania srodka do obnizania odziedziczonego ryzyka zachorowania na raka piersi lub jajnika |
| US9157122B2 (en) * | 2004-11-11 | 2015-10-13 | Garvan Institute Of Medical Research | Method of diagnosing cancer and reagents therefor |
| KR101138862B1 (ko) * | 2005-02-14 | 2012-05-14 | 삼성전자주식회사 | 단일염기 다형을 포함하는 유방암과 관련된 폴리뉴클레오티드, 그를 포함하는 마이크로어레이 및 진단 키트 및 그를이용한 유방암 진단 방법 |
| KR101206028B1 (ko) * | 2005-03-05 | 2012-11-28 | 삼성전자주식회사 | 유방암 특이적 다형성 서열을 이용한 유방암의 진단방법,유방암 특이적인 폴리뉴클레오티드 및 상기 폴리뉴클레오티드가 고정되어 있는 마이크로어레이 |
| US7858303B2 (en) * | 2005-03-14 | 2010-12-28 | Wisconsin Alumni Research Foundation | Method of analyzing breast cancer susceptibility and resistance |
| WO2006121991A2 (en) * | 2005-05-06 | 2006-11-16 | Diadexus, Inc. | Compositions and methods for detection, prognosis and treatment of breast cancer |
-
2008
- 2008-03-26 CN CN200880016394.2A patent/CN101874120B/zh not_active Expired - Fee Related
- 2008-03-26 US US12/302,473 patent/US20110117545A1/en not_active Abandoned
- 2008-03-26 EP EP08720170A patent/EP2137324A2/en not_active Withdrawn
- 2008-03-26 CA CA002681928A patent/CA2681928A1/en not_active Abandoned
- 2008-03-26 NZ NZ580490A patent/NZ580490A/xx not_active IP Right Cessation
- 2008-03-26 WO PCT/IS2008/000009 patent/WO2008117314A2/en not_active Ceased
- 2008-03-26 AU AU2008231425A patent/AU2008231425B2/en not_active Ceased
- 2008-03-26 KR KR1020097022257A patent/KR20090127939A/ko not_active Ceased
- 2008-03-26 EP EP12153902.7A patent/EP2527466A3/en not_active Withdrawn
- 2008-03-26 EP EP12153875.5A patent/EP2540840A3/en not_active Withdrawn
- 2008-03-26 EA EA200970891A patent/EA019953B1/ru not_active IP Right Cessation
- 2008-03-26 MX MX2009010439A patent/MX2009010439A/es active IP Right Grant
- 2008-03-26 JP JP2010500445A patent/JP5676245B2/ja not_active Expired - Fee Related
-
2009
- 2009-09-29 IL IL201217A patent/IL201217A/en not_active IP Right Cessation
- 2009-10-23 ZA ZA2009/07471A patent/ZA200907471B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2540840A2 (en) | 2013-01-02 |
| WO2008117314A2 (en) | 2008-10-02 |
| CN101874120B (zh) | 2015-01-14 |
| JP5676245B2 (ja) | 2015-02-25 |
| WO2008117314A3 (en) | 2008-12-18 |
| CA2681928A1 (en) | 2008-10-02 |
| EP2540840A3 (en) | 2013-05-15 |
| JP2010522555A (ja) | 2010-07-08 |
| MX2009010439A (es) | 2009-10-20 |
| ZA200907471B (en) | 2014-03-26 |
| EP2527466A2 (en) | 2012-11-28 |
| EA200970891A1 (ru) | 2010-04-30 |
| KR20090127939A (ko) | 2009-12-14 |
| EP2527466A3 (en) | 2013-05-15 |
| EP2137324A2 (en) | 2009-12-30 |
| NZ580490A (en) | 2012-08-31 |
| AU2008231425A1 (en) | 2008-10-02 |
| US20110117545A1 (en) | 2011-05-19 |
| IL201217A0 (en) | 2010-05-31 |
| CN101874120A (zh) | 2010-10-27 |
| EA019953B1 (ru) | 2014-07-30 |
| AU2008231425B2 (en) | 2014-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8580501B2 (en) | Genetic variants on chr 5p12 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment | |
| AU2007310412B2 (en) | Cancer susceptibility variants on Chr8q24.21 | |
| EP2329037B1 (en) | Genetic variants predictive of cancer risk | |
| US20110117545A1 (en) | Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment | |
| US8865400B2 (en) | Genetic variants contributing to risk of prostate cancer | |
| US8951735B2 (en) | Genetic variants for breast cancer risk assessment | |
| CA2729931A1 (en) | Genetic variants predictive of cancer risk in humans | |
| EP2451975A1 (en) | Genetic variants contributing to risk of prostate cancer | |
| WO2009069152A2 (en) | Genetic variants on chr hq and 6q as markers for prostate and colorectal cancer predisposition | |
| WO2010131268A1 (en) | Genetic variants for basal cell carcinoma, squamous cell carcinoma and cutaneous melanoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |